(Q37004359)

17 August 2017

1 reference

title

Pharmacotherapy of Alzheimer disease (English)

1 reference

17 August 2017

0 references

0 references

Dennis Seow

1

1 reference

PubMed ID

18020110

17 August 2017

Serge Gauthier

series ordinal

2

1 reference

PubMed ID

18020110

17 August 2017

language of work or name

English

0 references

publication date

1 October 2007

1 reference

Canadian Journal of Psychiatry

17 August 2017

1 reference

17 August 2017

52

1 reference

17 August 2017

10

1 reference

17 August 2017

620-629

1 reference

Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease

17 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Mild cognitive impairment: clinical characterization and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Prediction of probable Alzheimer's disease in memory-impaired patients: A prospective longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Vitamin E and donepezil for the treatment of mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Mild cognitive impairment: an operational definition and its conversion rate to Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Mild cognitive impairment--no benefit from vitamin E, little from donepezil

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Vascular dementia: a diagnostic challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

The GuidAge study: methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761 for prevention of Alzheimer disease in patients over 70 with a memory complaint

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Ampakines and the threefold path to cognitive enhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Randomized, double-blind, placebo-controlled international clinical trial of the Ampakine CX516 in elderly participants with mild cognitive impairment: a progress report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Potential treatment effects of donepezil not detected in Alzheimer's disease clinical trials: a physician survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Cholinesterase inhibitors for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Severe impairment battery. A neuropsychological test for severely demented patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Donepezil preserves cognition and global function in patients with severe Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Donepezil for severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Goal setting and attainment in Alzheimer's disease patients treated with donepezil

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Development and validation of the geriatric evaluation by relatives rating instrument (GERRI).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

A 26-week analysis of a double-blind, placebo-controlled trial of the ginkgo biloba extract EGb 761 in dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Clinical trials in mild cognitive impairment: lessons for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

NICE says anti-dementia drugs should be used only for moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Agitated behaviors in the elderly. I. A conceptual review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

A description of agitation in a nursing home

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Mild cognitive impairment as a clinical entity and treatment target

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Primary prevention trials in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Folic acid with or without vitamin B12 for cognition and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Hormone replacement therapy for cognitive function in postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Clinical trial of indomethacin in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Double placebo design in a prevention trial for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Midlife cardiovascular risk factors and risk of dementia in late life

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Statins and the risk of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Omega 3 fatty acid for the prevention of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

Mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201003

10.1177/070674370705201003

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

18020110